 |
 |
|
|
|
|
(Clinical Indication:Arteriosclerosis obliterans )
A discovery program for new anti-platelet drug had started from 1993 as collaboration between Dr. H. Hidaka and Otsuka Pharmaceutical Co. Ltd. K-134 was selected as a clinical candidate for anti-platelet drug with potent anti-intimal hyperplasic activity.
Phase I data demonstrate that K-134 exhibits good efficacy on platelet aggregation inhibition. In addition, K-134 also exhibits potent anti-intimal hyperplasic activity in animal models.
All patent rights for world-wide marketing were devolved from Otsuka Pharmaceutical Co., Ltd. by August 2002, and then out-licensed to Kowa Co., Ltd. in September 2002. Phase II trials are successfully completed in the US and Japan.
(Clinical Indication:Glaucoma)
K-115, isoquinolinesulfonamide compound, is a selective Rho-kinase inhibitor; being developed as an anti-glaucoma drug with intraocular pressure (IOP)-lowering activities. Preclinical studies and Phase I trials of K-115 demonstrate that instillations of K-115 reduced IOP. In addition, K-115 demonstrated neuroprotection of retinal ganglion cells which are known to be injured in glaucoma. DWTI licensed out the world-wide rights of K-115 to Kowa Co., Ltd. in September 2002.
Phase II trial is successfully completed in Japan.
(Clinical Indication:Cancer)
HMN-214 was invented as an anti-cancer drug under collaboration between Dr. Hidaka and Nippon Shinyaku Co. Ltd. A study by using Drug Western method indicates that HMN-214 has a novel mechanism of action. Preclinical studies demonstrated HMN-214 possessed equal or more potent anti-tumor activity than that of other commercialized anti-cancer drugs, while adverse effects of HMN-214 is considered to be similar to those of typical anti-cancer drugs.
DWTI licensed-out the world-wide rights of HMN-214 to Nippon Shinyaku Co., Ltd. in March 2001. Nippon Shinyaku Co., Ltd. had completed Phase I trials in US.
|
|
|
| | | | |
| |
|
 |
